SCHEDULE TO
This Tender Offer Statement on Schedule TO (this Tender Offer Statement) relates to an offer (the Exchange
Offer) by Illumina, Inc., a Delaware corporation (the Company), to exchange newly issued shares of the Companys common stock, par value $0.01 per share (the Common Stock), or cash, on the terms and subject to the
conditions described in the offer to exchange, dated November 15, 2021 (as the same may be amended from time to time, the Offer to Exchange), filed as Exhibit (a)(1)(A) hereto, and in the related letter of transmittal (as the same
may be amended from time to time, the Letter of Transmittal), filed as Exhibit (a)(1)(B) hereto, for any and all outstanding contingent value rights (CVRs) issued pursuant to the Contingent Value Rights Agreement, dated as of
August 18, 2021 (the CVR Agreement), among the Company, Computershare Trust Company, N.A., a federally chartered trust company, as Trustee, and Shareholder Representative Services LLC, a Colorado limited liability company, as Holder
Representative.
This Tender Offer Statement is intended to satisfy the reporting requirements of Rule 13e-4 under the Securities Exchange Act of 1934, as amended. The information contained in the Offer to Exchange and the related Letter of Transmittal is incorporated by reference herein in response to all of the
items of this Schedule TO, as more particularly described below.
Item 1.
|
Summary Term Sheet.
|
The information set forth under the heading Summary Term Sheet in the Offer to Exchange is incorporated by
reference herein.
Item 2.
|
Subject Company Information.
|
(a) Name and Address. The name of the Company and the address and telephone number of its
principal executive offices are as follows:
Illumina, Inc.
5200 Illumina Way
San Diego, CA 92122
(858) 202-4500
(b) Securities. The information set forth on the front cover page of the Offer to
Exchange is incorporated by reference herein.
(c) Trading Market and Price. The
information with respect to the CVRs set forth in the Offer to Exchange under the heading Market Price and Dividend Information is incorporated by reference herein.
Item 3.
|
Identity and Background of Filing Person.
|
(a) Name and Address. The filing person is the Company. The business address and telephone number of the Company are as
set forth under Item 2(a) above and are incorporated by reference herein.
Pursuant to Instruction C to Schedule TO, the
following persons are the directors and/or executive officers of the Company:
|
|
|
|
|
|
|
Name
|
|
Position
|
|
|
Francis deSouza
|
|
President and Chief Executive Officer
|
|
|
Alex Aravanis
|
|
Chief Technology Officer, Head of Research and Product Development
|
|
|
Charles E. Dadswell
|
|
General Counsel and Secretary
|
|
|
Phil Febbo
|
|
Chief Medical Officer
|
|
|
Joydeep Goswami
|
|
Chief Strategy and Corporate Development Officer
|